Latest close
$434.03
As of Oct 15, 2026
| Fund | Portfolio weight | Shares | Change vs prev. quarter |
|---|---|---|---|
| Matrix Asset Advisors | 3.03% | 102,817 | ADDED (+3.0%) |
| Torray Funds | 2.92% | 59,771 | ADDED (+10.7%) |
| Sarasin & Partners | 1.46% | 343,948 | TRIMMED (-48.4%) |
| Mairs & Power Funds | 0.02% | 4,924 | TRIMMED (-0.8%) |
| Atalanta Sosnoff Capital | 0.01% | 863 | TRIMMED (-11.8%) |
| Dodge & Cox Funds | <0.01% | 12,817 | TRIMMED (-4.1%) |
Source: SEC Form 13F filings for the quarter ended Jun 30, 2026. Change labels compare each fund’s 2026 Q2 filing with its previous filing. 13F filings cover long positions only and arrive up to 45 days after quarter-end. Fund counts here aggregate every share class mapped to this ticker; research headlines cite filer counts as they stood at publication, so a count here can differ from a headline by a holder (see Methodology, "How holder counts are counted").
Exited this quarter: Check Capital Management, OrbiMed Advisors.
| Institutions holding | 3,157 of 8,857 filers |
| Long-only filers among them | 3,145 |
| Change vs 2026 Q1 | +50 net · 2,012 entered · 1,962 exited |
| Shares reported, all filers | 442,059,192 |
| Reported value, all filers | $159.3B |
Source: SEC Form 13F data sets — every filer's latest report for the quarter ended Jun 30, 2026, not just the tracked funds above; changes compare with the quarter ended Mar 31, 2026. Share counts and values are summed as reported in the filings (a small number of filers report values in thousands of dollars, so value totals are as-filed sums).
| Exchange | Nasdaq |
| Industry | Biological Products, (No Diagnostic Substances) (SIC 2836) |
| Revenue · FY2025 | $36.8B |
| Net income · FY2025 | $7.7B |
| Total assets · FY2025 | $90.6B |
| Shares outstanding | 540,632,005 |
| Market cap (at latest close) | $234.7B |
Source: SEC EDGAR company filings (submissions and company facts), collected Oct 7, 2026. Shares outstanding as reported Jul 30, 2026.
| Shares short · Sep 15, 2026 | 14,063,517 |
| Share of shares outstanding | 2.60% |
| Days to cover | 4.94 |
Shares short at recent settlements — Jun 30, 2026: 12.9M · Jul 15, 2026: 12.8M · Jul 31, 2026: 13.3M · Aug 14, 2026: 12.0M · Aug 31, 2026: 13.0M · Sep 15, 2026: 14.1M.
Source: FINRA Equity Short Interest (biweekly settlement data). Shares outstanding from SEC filings as of Jul 30, 2026.
0 insiders bought on the open market in the last 90 days (0 purchases, $0), against 6 sales by 3 insiders ($4.1M).
Source: SEC Form 4 filings, as of Oct 16, 2026. Open-market transactions only.
1 member of Congress reported buying (2 purchases vs 3 sales). Bought by Republicans. Latest buy: Sep 22, 2026.
Source: U.S. House Clerk and U.S. Senate eFD STOCK Act periodic transaction reports, as of Oct 3, 2026. Reported amounts are ranges, and reports can arrive up to 45 days after the trade.
Politicians
· Bought by Members — Last 6 months: bought by a member of the U.S. Congress
Financial Screens
· Buffett — Companies with high ROE sustained for more than a decade
· Growth — Revenue up every year for 5 straight years
· Dividend Growth — Dividends raised for more than 10 years
· Earnings Quality (Cash Conversion) — Profits that actually come back as cash
· Earnings Stability — Small earnings swings and almost no loss years
Chart Signals
· Monthly Uptrend — Price above its 12-month moving average
· Top Relative Strength — Top 20% of the universe by 6-month return
Key figures
· Buffett — Latest ROE: 89.1% · Years ROE ≥15% (of 10): 9 · 10-yr avg ROE: 79.2% · Latest net income: $7.7B
· Growth — Latest revenue: $36.8B · 5-yr revenue CAGR: 7.6% · Straight growth years: 6
· Dividend Growth — Dividend per share: 9.66 · Dividend yield: 2.3% · Straight dividend years: 10 · 10-yr dividend growth: 132.8%
· Earnings Quality (Cash Conversion) — Cash conversion (3-yr avg): 1.79 · Operating cash flow: $10.0B · Net income: $7.7B
· Earnings Stability — Earnings variation (CV): 0.29 · Loss years (of 10): 0 · Latest net income: $7.7B
· Bought by Members — Members buying: 1 · Buy txns: 2 · Sell txns: 3 · Latest buy: Sep 22, 2026
Financial screens are computed from SEC company financial statements; red-flag models are screens, not verdicts — see Methodology.
· Politician BEST — appeared in 10 of the last 20 quarterly lists; latest 2026 Q1, ranked #32 of 50.
| 13F signal (2021 Q3 – 2026 Q1) | Events | Win rate | Avg return | SPY | Excess |
|---|---|---|---|---|---|
| Heavy accumulation — 3+ tracked funds increased together | 10 | 70.0% | +4.7% | +3.5% | +1.2% |
| Share count tripled (3x) | 1 | 0.0% | -6.1% | -2.5% | -3.6% |
| Heavy exit — 3+ tracked funds sold out together | 1 | 100.0% | +9.6% | +5.6% | +4.0% |
Measured from SEC 13F filings: entry at the close on the first trading day after each quarter’s filing deadline, exit one quarter later on the same rule, dividend-adjusted closes. Past records do not guarantee future results — see Track Record and Methodology.
Also held by the tracked funds that hold AMGN: AMAZON COM INC (AMZN) · MICROSOFT CORP (MSFT) · Alphabet Inc. (GOOGL) · VISA INC. (V) · Alphabet Inc. (GOOG) · NVIDIA CORP (NVDA) · Apple Inc. (AAPL) · Broadcom Inc. (AVGO) · JPMORGAN CHASE & CO (JPM) · ELI LILLY & Co (LLY).
Open the interactive tool →Live screens, charts and backtests for every tracked stock, fund and signal — free, no sign-up.